Amphastar Pharmaceuticals, Inc.
- Last sale
- Oct 30, 2026 · +2.89%
- Market cap
- $1.18B
- 42.65M shares
- Filings
- 959
Q3 2026−1.7% FY25 yoy
Q3 2026−38.5% FY25 yoy
Q3 2026−31.7% FY25 yoy
Q3 2026derived−29.7% FY25 yoy
Q3 2026−33.7% FY25 yoy
Q3 2026+12.2% FY25 yoy
- $1.18B
- 12.0×
- 1.6×
- 1.5×
- 11.75%
- —
Twelve months to Sep 30, 2026 · derived
Price
Oct 30, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $719,887,000 | reported | |
| FY 2024 | 2024-12-31 | $731,967,000 | reported | |
| FY 2023 | 2023-12-31 | $644,395,000 | reported | |
| FY 2022 | 2022-12-31 | $498,987,000 | reported | |
| FY 2021 | 2021-12-31 | $437,768,000 | reported | |
| FY 2020 | 2020-12-31 | $349,846,000 | reported | |
| FY 2019 | 2019-12-31 | $322,357,000 | reported | |
| FY 2018 | 2018-12-31 | $294,666,000 | reported | |
| FY 2017 | 2017-12-31 | $240,175,000 | reported | |
| FY 2016 | 2016-12-31 | $255,165,000 | reported | |
| FY 2015 | 2015-12-31 | $251,519,000 revised | reported | |
| FY 2014 | 2014-12-31 | $210,461,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $75.59M | $75.59M | — | 45.37M sh | −4.8% | 62.3% |
| FY2024 | — | $85.46M | $85.46M | — | 47.65M sh | −0.9% | 49.6% |
| FY2023 | — | $58.14M | $58.14M | — | 48.10M sh | +0.4% | 40.0% |
| FY2022 | — | $39.91M | $39.91M | — | 47.90M sh | −0.5% | 61.3% |
| FY2021 | — | $28.87M | $28.87M | — | 48.15M sh | +1.5% | 40.9% |
Segments
LineFY2025ShareChange
Pharmaceutical products segment$719.89M100%−1.7%
Active Pharmaceutical Ingredient Segment———
Finished Pharmaceutical Products Segment———
Total$719.89M
Pharmaceutical preparations
Amphastar Pharmaceuticals, Inc. is the 45th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
TLXTelix Pharmaceuticals Ltd$803.8M55.6%0.9%—COLLCollegium Pharmaceutical, Inc$780.6M23.6%8.1%$776.1MCORTCorcept Therapeutics Inc$761.4M12.8%13.1%$8.1BEBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPCRXPacira BioSciences, Inc.$726.4M3.6%1.0%$1.5B
AMPHAmphastar Pharmaceuticals, Inc. (this company)$719.9M1.7%13.6%$1.2B
KNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BRAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BAXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR